论文部分内容阅读
一、慢性粒细胞白血病治疗现况慢性粒细胞白血病(简称慢粒)在白血病中约占15%。自50年代初应用马利兰治疗后,20多年来,进展仍然不大。马利兰虽可改善患者有效生命,但存活期仅能延长数月至20余月,其中还可能包括诊断时问较过去提前的成份,不能根治,疗效比1865年 Lissauer 氏倡用的砷剂仅稍有提高。马利兰的近期疗效与使用方便安全,也限制了慢粒治疗的进一步研究。慢粒死亡原因中,药物性骨髓抑制占5%;其它与白血病无关原因占15%;急变则占80%。预防或延缓急变的发生是提高慢粒疗效的主要关键。
First, the treatment of chronic myelogenous leukemia Chronic myeloid leukemia (referred to as CML) accounts for about 15% of leukemia. After more than two decades of treatment with marilan in the early 1950s, there has been little progress. Although Maryland can improve the patient’s effective life, but the survival period can only be extended for months to 20 months, which may include more advanced diagnostic time than the ingredients, can not cure, curative effect than the 1865 Lissauer’s arsenic only slightly Improve. Recent benefits and ease of use of Maryland are safe and limit the further study of CML. Among the causes of death from CML, drug-induced bone marrow suppression accounted for 5%; other causes unrelated to leukemia accounted for 15%; acute changes accounted for 80%. Preventing or slowing the occurrence of acute changes is the key to improving the efficacy of CML.